Pharmaceutical - Asia-Pacific, Inflammatory diseases

Filter

Popular Filters

In Japan, Mitsubishi Tanabe files for canagliflozin approval; Eisai/AbbVie's Humira gets new indication

28-05-2013

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) said yesterday (May 27) that it has submitted…

AbbVieAsia-PacificBiotechnologycanagliflozinDiabetesEisaiHumiraInflammatory diseasesInvokanaMitsubishi TanabePharmaceuticalRegulation

AstraZeneca partners with WuXi AppTec to speed novel biologic to Chinese market

11-09-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has formed a joint venture with China's WuXi AppTec to…

Anti-Arthritics/RheumaticsAsia-PacificAstraZenecaBiotechnologyImmunologicalsInflammatory diseasesMEDI5117MedImmuneMergers & AcquisitionsPharmaceuticalResearchWuXi Apptec

Evotec out-licenses EVT 401 in China to Conba Pharma

03-05-2012

Hamburg, Germany-based Evotec AG (EVT: TecDAX) has granted a development and marketing license on EVT…

Asia-PacificConba PharmaceuticalsEvotecInflammatory diseasesLicensingPharmaceutical

Company Spotlight

ImmunoGen

ImmunoGen

Back to top